angiographic restenosis

angiographic restenosis

A term of art used in interventional cardiology for greater than 50%-diameter stenosis at follow-up of a previously treated artery.
References in periodicals archive ?
One month follow-up C-reactive protein may be a useful predictor of angiographic restenosis and long-term clinical outcomes after bare metal stent implantation.
Clinical data from the Horizons-AMI trial showed that, in patients with AMI, paclitaxel-eluting stents were superior in efficacy to bare-metal stents, significantly reducing clinical and angiographic restenosis compared to bare-metal stents, while demonstrating a comparable safety profile at three years.
01mm), a binary angiographic restenosis rate of 0%, and no acute or late stent thrombosis.
Stone, a professor of medicine at Columbia University Medical Center/New York-Presbyterian Hospital, has revealed that in patients undergoing angioplasty, the use of paclitaxel-eluting stents has been found to reduce rates of target lesion revascularization (TLR) and binary angiographic restenosis when compared to the use of bare-metal stents after 1 year.
The rate of binary angiographic restenosis at 6 months after treatment was 20% in the sirolimus-eluting stent group and 30% in the brachytherapy group; the difference just missed statistical significance.
Predictors of angiographic restenosis after stenting: Pooled analysis of 1197 patients with protocol-mandated angiographic follow-up from five randomized stent trials.
A repeat angiographic study was performed after for detection of angiographic restenosis at 6 months, and [greater than or equal to] 50% diameter stenosis at the site of intervention was considered indicative of restenosis.
HORIZONS-AMI demonstrated that the TAXUS Express Stent significantly reduced clinical and angiographic restenosis compared to an otherwise identical bare-metal Express control stent.
Heme oxygenase-1 gene promotor microsatellite polymorphism is associated with angiographic restenosis after coronary stenting.
Patients who received sirolimus-eluting stents also had significantly less angiographic restenosis compared with those who got paclitaxel-eluting stents, 6.
A meta analysis of several randomized trials comparing drug eluting stents (DES) both with and without polymers and bare metal stents (BMS) revealed a significant and persistent progression in clinical and angiographic restenosis in DES up to 36/48 months of over 60%.